Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis

doi:10.1021/acsnano.3c06626

KIB OpenIR

	Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis
	Niu,Xia; Meng,Yanan; Cui,Jinjin; Li,Rui; Ding,Xiao; Niu,Bingyu; Chang,Ge; Xu,Ning; Li,Guiling; Wang,Yucheng; Wang,Lulu
	2023
发表期刊	ACS NANO
ISSN	1936-086X
卷号	17 期号:23 页码:23608-23625
摘要	Liver fibrosis is a major contributor to the morbidity and mortality associated with liver diseases, yet effective treatment options remain limited. Hepatic stellate cells (HSCs) are a promising target for hepatic fibrogenesis due to their pivotal role in disease progression. Our previous research has demonstrated the potential of Dihydrotanshinone I (DHI), a lipophilic component derived from the natural herb Salvia miltiorrhiza Bunge, in treating liver fibrosis by inhibiting the YAP/TEAD2 interaction in HSCs. However, the clinical application of DHI faces challenges due to its poor aqueous solubility and lack of specificity for HSCs. Additionally, recent studies have implicated the impact of liver microbiota, distinct from gut microbiota, on the pathogenesis of liver diseases. In this study, we have developed an HSC- and microbiome-specific delivery system for DHI by conjugating prebiotic-like cyclodextrin (CD) with vitamin A, utilizing PEG2000 as a linker (VAP2000@CD). Our results demonstrate that VAP2000@CD markedly enhances the cellular uptake in human HSC line LX-2 and enhances the deposition of DHI in the fibrotic liver in vivo. Subsequently, intervention with DHI-VAP2000@CD has shown a notable reduction in bile duct-like structure proliferation, collagen accumulation, and the expression of fibrogenesis-associated genes in rats subjected to bile duct ligation. These effects may be attributed to the regulation of the YAP/TEAD2 interaction. Importantly, the DHI-VAP2000@CD intervention has also restored microbial homeostasis in the liver, promoting the amelioration of liver inflammation. Overall, our findings indicate that DHI-VAP2000@CD represents a promising therapeutic approach for liver fibrosis by specifically targeting HSCs and restoring the liver microbial balance.
关键词	liver fibrosis dihydrotanshinone I hepaticstellate cells vitamin A cyclodextrin liver microbiome STRATEGY THERAPY TARGET NANOPARTICLES PATHWAY
DOI	10.1021/acsnano.3c06626
收录类别	SCI
WOS记录号	WOS:001124705100001
引用统计
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/75276
专题	中国科学院昆明植物研究所
推荐引用方式 GB/T 7714	Niu,Xia,Meng,Yanan,Cui,Jinjin,et al. Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis[J]. ACS NANO,2023,17(23):23608-23625.
APA	Niu,Xia.,Meng,Yanan.,Cui,Jinjin.,Li,Rui.,Ding,Xiao.,...&Wang,Lulu.(2023).Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis.ACS NANO,17(23),23608-23625.
MLA	Niu,Xia,et al."Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis".ACS NANO 17.23(2023):23608-23625.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
10.1021_acsnano.3c06（5563KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览下载